Pfizer Pre-Tax Profit Margin 2010-2023 | PFE

Current and historical pre-tax profit margin for Pfizer (PFE) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Pfizer pre-tax profit margin for the three months ending December 31, 2023 was .
Pfizer Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2023-12-31 $58.50B $1.06B 1.81%
2023-09-30 $68.54B $10.42B 15.20%
2023-06-30 $77.94B $22.77B 29.21%
2023-03-31 $92.95B $31.95B 34.37%
2022-12-31 $100.33B $34.73B 34.61%
2022-09-30 $99.88B $33.33B 33.37%
2022-06-30 $101.28B $32.17B 31.76%
2022-03-31 $92.43B $27.67B 29.93%
2021-12-31 $81.29B $24.31B 29.91%
2021-09-30 $68.88B $21.08B 30.61%
2021-06-30 $55.12B $13.81B 25.05%
2021-03-31 $46.08B $9.89B 21.45%
2020-12-31 $41.65B $7.04B 16.89%
2020-09-30 $32.07B $-1.43B -4.47%
2020-06-30 $34.47B $8.73B 25.31%
2020-03-31 $37.87B $9.84B 25.98%
2019-12-31 $40.91B $11.32B 27.68%
2019-09-30 $40.22B $9.95B 24.75%
2019-06-30 $40.84B $3.40B 8.34%
2019-03-31 $41.04B $3.79B 9.24%
2018-12-31 $40.83B $3.59B 8.80%
2018-09-30 $53.37B $13.79B 25.83%
2018-06-30 $53.24B $13.19B 24.78%
2018-03-31 $52.67B $12.48B 23.70%
2017-12-31 $52.55B $12.31B 23.42%
2017-09-30 $52.47B $12.13B 23.11%
2017-06-30 $52.35B $10.15B 19.38%
2017-03-31 $52.60B $8.74B 16.62%
2016-12-31 $52.82B $8.35B 15.81%
2016-09-30 $53.24B $7.22B 13.56%
2016-06-30 $52.29B $8.32B 15.90%
2016-03-31 $50.99B $9.44B 18.52%
2015-12-31 $48.85B $8.97B 18.35%
2015-09-30 $47.92B $11.12B 23.21%
2015-06-30 $48.20B $12.01B 24.92%
2015-03-31 $49.12B $12.48B 25.40%
2014-12-31 $49.61B $12.24B 24.67%
2014-09-30 $50.05B $13.50B 26.97%
2014-06-30 $50.33B $13.48B 26.79%
2014-03-31 $50.53B $14.84B 29.37%
2013-12-31 $51.58B $15.72B 30.47%
2013-09-30 $50.88B $14.48B 28.45%
2013-06-30 $51.19B $13.71B 26.78%
2013-03-31 $52.18B $12.53B 24.02%
2012-12-31 $54.66B $11.24B 20.57%
2012-09-30 $53.25B $10.65B 19.99%
2012-06-30 $56.90B $11.38B 20.00%
2012-03-31 $59.42B $10.80B 18.17%
2011-12-31 $61.04B $11.48B 18.81%
2011-09-30 $65.06B $11.24B 17.28%
2011-06-30 $64.44B $9.11B 14.14%
2011-03-31 $65.09B $9.44B 14.50%
2010-12-31 $65.17B $9.47B 14.53%
2010-09-30 $65.50B $8.34B 12.73%
2010-06-30 $61.13B $10.90B 17.83%
2010-03-31 $54.98B $10.02B 18.23%
2009-12-31 $49.27B $10.67B 21.66%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $150.148B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $743.142B 123.75
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
Merck (MRK) United States $321.545B 84.64
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80